Rani Therapeutics' preclinical successes with RT-116 and RT-114 in 2025 significantly enhance its position in the oral GLP-1/GLP-2 market by validating its RaniPill® platform for oral delivery of these critical therapeutic agents.
Key Preclinical Achievements in 2025
- RT-116 (Oral Semaglutide): In February 2025, Rani announced preclinical data demonstrating that RT-116, an oral semaglutide delivered via the RaniPill® HC, achieved comparable bioavailability, pharmacokinetics, and weight loss to subcutaneously administered semaglutide. This data also indicated RT-116 was well tolerated with no serious adverse events.1 This success was further highlighted at ObesityWeek® 2025 in November.2
- RT-114 (Oral GLP-1/GLP-2 Dual Agonist): March 2025 saw the release of preclinical data showing RT-114, an oral GLP-1/GLP-2 dual agonist (PG-102 developed with ProGen Co., Ltd.), achieved bioequivalence to its subcutaneously administered counterpart. RT-114 demonstrated a relative bioavailability of 111% and comparable pharmacokinetic profiles and weight loss.1 These findings were also presented at ENDO 2025 in July.3
Market Positioning and Strategic Implications
These preclinical results underscore the potential of Rani's RaniPill® platform to transform injectable biologics into convenient oral therapies, a significant advantage in the competitive GLP-1/GLP-2 market.1
- Convenience and Accessibility: The successful oral delivery of these agents suggests a pathway to more convenient and accessible treatment options for conditions like obesity, which could improve patient adherence.1
- "First-in-Class" Potential: Rani positions RT-114 as a potential "first-in-class" orally administered bispecific GLP-1/GLP-2 receptor agonist, aiming to fill a crucial gap in the current treatment landscape for obesity.1
- Advancement to Clinical Trials: The planned initiation of a Phase 1 clinical trial for RT-114 by the end of 2025 marks a critical step towards further clinical development and potential commercialization.3
- Platform Validation and Partnerships: The consistent preclinical success across multiple incretin-based molecules validates the versatility of the RaniPill® platform. This validation is further supported by strategic collaborations, such as the co-development agreement for RT-114 with ProGen and the broader collaboration with Chugai Pharmaceutical Co., Ltd. announced in October 2025, which underscores external confidence in Rani's technology.1
These developments collectively strengthen Rani Therapeutics' competitive stance by demonstrating the feasibility of its oral delivery technology for highly sought-after GLP-1/GLP-2 agonists, potentially disrupting a market currently dominated by injectable formulations.
